Is Adagraxibu (Krazati) available in Hainan Boao Lecheng and the process guide

Adagrasiib (Krazati) is a KRAS G12C mutation inhibitor indicated for the treatment of KRAS G12C-positive advanced or metastatic non-small cell lung cancer (NSCLC). At present, the drug has not been officially launched in China, but in some medical institutions in the Hainan Boao Lecheng International Medical Tourism Pilot Zone, patients can obtain it through "overseas drug purchase".

The process of purchasing drugs in Boao Lecheng usually includes: First, patients need to hold a prescription issued by a doctor and confirm that they comply with the relevant policies and conditions of the National Medical Products Administration (NMPA) for "overseas drug purchase". Secondly, patients need to go to the designated medical institution in Boao Lecheng, submit relevant information and complete the drug application and approval process. After approval, patients can purchase adagrasib through formal channels and use it under the guidance of medical institutions.

It should be noted that although Hainan Boao Lecheng provides a way to obtain adagrasibu, patients still need to follow the relevant regulations of the State Food and Drug Administration to ensure that the drug purchase process is legal and compliant. In addition, before using adagrasib, patients should fully understand the drug's indications, dosage, possible side effects and interactions with other drugs, and conduct treatment under the guidance of a professional doctor.
In short, the availability of adagrasib in Hainan Boao Lecheng provides patients with new treatment options, but patients should strictly abide by relevant regulations during the purchase and use of drugs to ensure the safety and effectiveness of treatment. If you have any questions, it is recommended to consult local medical institutions or professional doctors.
Reference: https://www.drugs.com/